Cloris Xue
Overview
Explore the profile of Cloris Xue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan Y, Drilon A, Chiu C, Loong H, Siena S, Krzakowski M, et al.
Clin Lung Cancer
. 2024 Jan;
25(2):e81-e86.e4.
PMID: 38245456
No abstract available.
2.
Hurvitz S, Bardia A, Quiroga V, Park Y, Blancas I, Alonso-Romero J, et al.
Lancet Oncol
. 2023 Sep;
24(9):1029-1041.
PMID: 37657462
Background: The development of more potent selective oestrogen receptor antagonists and degraders (SERDs) that can be orally administered could help to address the limitations of current endocrine therapies. We report...
3.
Ascierto P, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al.
Lancet Oncol
. 2022 Dec;
24(1):33-44.
PMID: 36460017
Background: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in...
4.
Sandhu S, Atkinson V, Gonzalez Cao M, Medina T, Soria Rivas A, Menzies A, et al.
Eur J Cancer
. 2022 Dec;
178:180-190.
PMID: 36455412
Objective: To evaluate the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAF wild-type melanoma who had progressed on prior anti‒programmed death-1 (PD-1) therapy....
5.
Barteselli G, Goodman G, Patel Y, Caro I, Xue C, McCallum S
Drug Saf
. 2022 Oct;
45(12):1491-1499.
PMID: 36310331
Introduction And Objective: Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due...
6.
de Azevedo S, de Melo A, Roberts L, Caro I, Xue C, Wainstein A
Pigment Cell Melanoma Res
. 2021 Jan;
34(5):973-977.
PMID: 33476492
Anti-programmed death-1 agents are an established option for advanced melanoma, but the anti-programmed death-ligand 1 (anti-PD-L1) antibody atezolizumab, an agent approved for the treatment of multiple solid tumors, was not...
7.
Brezden-Masley C, Fathers K, Coombes M, Pourmirza B, Xue C, Jerzak K
Breast Cancer Res Treat
. 2020 Oct;
185(3):807-815.
PMID: 33090268
Purpose: We sought to expand the currently limited, Canadian, population-based data on the characteristics, treatment pathways, and health care costs according to stage in patients with human epidermal growth factor...
8.
Brezden-Masley C, Fathers K, Coombes M, Pourmirza B, Xue C, Jerzak K
Breast Cancer Res Treat
. 2020 Oct;
185(2):507-515.
PMID: 33064230
Purpose: To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-)...
9.
Brezden-Masley C, Fathers K, Coombes M, Pourmirza B, Xue C, Jerzak K
Cancer Med
. 2020 Aug;
9(20):7548-7557.
PMID: 32862501
Background: There have been few publications exploring the characteristics, treatment pathways, and health-care costs by stage in patients with a triple-negative breast cancer (TNBC) phenotype. Methods: Data from a publicly...